COVID-19 Treatment, Testing Costs Could Reach $417 Billion Over Next Year

With the novel coronavirus spreading across the nation, both private health insurers and public payers could see heavy economic costs. According to a recent paper prepared by Wakely Consulting Group on behalf of America’s Health Insurance Plans, under the baseline risk scenario with a U.S. infection rate of 20%, allowed costs could range from $112.5 billion to $185.4 billion over 2020 and 2021 combined. As the ultimate number and severity of COVID-19 cases remain unknown, the estimates have a wide range. Graphics below highlight three different organizations’ estimates for how the pandemic will change U.S. health care costs.

0 Comments
© 2024 MMIT
Jinghong Chen

Jinghong Chen Reporter

Jinghong has been producing infographics and data stories on employer-sponsored insurance, public health insurance programs and prescription drug coverage for AIS Health’s Health Plan Weekly and Radar on Drug Benefits since 2018. She also manages AIS Health’s annual executive compensation database for top insurers and Blue Cross and Blue Shield affiliates. Before joining AIS Health, she interned at WBEZ, Al Jazeera English and The New York Times Chinese. She graduated from Missouri School of Journalism with a focus on data journalism and international reporting.

Related Posts

supreme-court
October 4

Will Supreme Court Review Preventive Services Coverage Case?

READ MORE
medicare-advantage-sign
October 4

MA Star Ratings Drama: Humana Gets Bad News, UnitedHealth Sues CMS

READ MORE
wall-street-sign
October 4

Unsurprising or Unlikely? Analysts React to Prospect of CVS Breakup

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today